Literature DB >> 11994179

Anticonvulsant hypersensitivity syndrome.

Sukhjot Kaur1, Rashmi Sarkar, Gurvinder P Thami, Amrinder J Kanwar.   

Abstract

Anticonvulsant hypersensitivity syndrome is an acute, life-threatening, idiosyncratic drug reaction seen with the aromatic antiepileptic drugs, phenytoin, carbamazepine, phenobarbital, and primidone, with frequent cross sensitivity. It usually occurs 2-8 weeks after initiation of therapy and the hallmark clinical features are fever, rash, and lymphadenopathy. Hematologic abnormalities such as eosinophilia, atypical lymphocytes, and internal organ involvement also occur with varying severity. A case of hypersensitivity syndrome due to carbamazepine with cross sensitivity to phenytoin is reported. It is emphasized that this serious drug reaction with diverse clinical presentations should be recognized and treated promptly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994179     DOI: 10.1046/j.1525-1470.2002.00045.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  4 in total

1.  DRESS syndrome with fatal results induced by sodium valproate in a patient with brucellosis and a positive cytoplasmic antineutrophilic cytoplasmic antibody test result.

Authors:  Fatih Albayrak; Serkan Cerrah; Ayse Albayrak; Hakan Dursun; Rahsan Yildirim; Abdullah Uyanik
Journal:  Rheumatol Int       Date:  2010-03-31       Impact factor: 2.631

2.  Probable Anticonvulsant Hypersensitivity Syndrome Due to Fosphenytoin in a Pediatric Patient with Streptococcus pneumoniae Meningitis.

Authors:  Nancy J Gadd
Journal:  J Pediatr Pharmacol Ther       Date:  2007-10

3.  Cross Hypersensitivity Syndrome between Phenytoin and Carbamazepine.

Authors:  Nerea Moyano Sierra; Benito García; Javier Marco; Susana Plaza; Francisco Hidalgo; Teresa Bermejo
Journal:  Pharm World Sci       Date:  2005-06

4.  Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome.

Authors:  Cheol-Woo Kim; Gwang-Seong Choi; Chang-Ho Yun; Deok-In Kim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.